Found 24 Acute Myeloid Leukemia trials
A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS) (ACCESS)
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for …
Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
Pleae refer to Section 3 (Objectives and Endpoints) of the full protocol Please refer to Section 3.1 (Primary Endpoint) of the full protocol Please refer to Section 3.2 (Secondary Endpoints) of the full protocol
Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
UPCC 42422: A Phase 1/2 Multicenter Open-Label Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with acute myeloid leukemia with changed FLT3 gene where chemo is not an option due to old age/other conditions. Aims of this study: find suitable doses of gilteritinib, venetoclax and azacitidine as combined treatment; to learn how …
UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Request for collaborative review: WIRB serving as IRB of record.
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) (CATHY)
The study compares two acute graft-versus-host disease (aGVHD) prophylaxis regimens: CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX) versus placebo/tacrolimus / methotrexate (placebo/Tac/MTX) in the setting of myeloablative conditioning (MAC), matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation in participants with acute leukemia (AML/ALL) or myelodysplastic syndrome (MDS).
UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
UPCC 03722 A prospective randomized double-blind placebo-controlled multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
Please choose between Voice or SMS based delivery of verification code
or